Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study-Reference-Cited by-同舟云学术

Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study

Published:2023-12 Issue: Volume:28 Page:100629
ISSN:2667-193X
Container-title:The Lancet Regional Health - Americas
language:en
Short-container-title:The Lancet Regional Health - Americas

Author:

Shoukat Affan,Abdollahi Elaheh,Galvani Alison P.,Halperin Scott A.,Langley Joanne M.,Moghadas Seyed M.^ORCID

Funder

The Notsew Orm Sands Foundation

Natural Sciences and Engineering Research Council of Canada

Canada Foundation for Innovation

Canadian Immunization Research Network

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Internal Medicine,Health Policy

Reference66 articles.

1. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study;Shi;Lancet,2017

2. Respiratory syncytial virus—a comprehensive review;Borchers;Clin Rev Allergy Immunol,2013

3. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis;Li;Lancet,2022

4. Health care costs of hospitalization of young children for respiratory syncytial virus infections: a population-based matched cohort study;Thampi;CMAJ Open,2021

5. Burden of respiratory syncytial virus hospitalizations in Canada;Mitchell;Can Respir J,2017

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nirsevimab: Alleviating the burden of RSV morbidity in young children;Journal of Paediatrics and Child Health;2024-08-16

2. Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants;Vaccine;2024-08

3. Independent Analysis of the Results of the First Infant Immunization Campaign with Beyfortus® (Nirsevimab, Monoclonal Antibody Against RSV Bronchiolitis Virus): Mixed Results, Identification of Biases, and Possible Role and Mechanisms of ADE (Antibody Dependent Enhancement);2024-06-11

4. Cost-Effectiveness Analysis of Maternal Respiratory Syncytial Virus Vaccine in Protecting Infants from RSV Infection in Japan;Infectious Diseases and Therapy;2024-06-05

5. A Health Economic Evaluation for Implementing an Extended Half-life Monoclonal Antibody for All Infants vs. Standard Care for Respiratory Virus Syncytial Prophylaxis in Canada;2024-03-28